recent
discoveri
new
potent
therapeut
molecul
reach
clinic
due
poor
deliveri
low
bioavail
made
deliveri
key
stone
therapeut
develop
sever
technolog
design
improv
cellular
uptak
therapeut
molecul
includ
cellpenetr
peptid
cpp
cpp
first
discov
base
potenc
sever
protein
enter
cell
numer
cpp
describ
far
group
two
major
class
first
requir
chemic
linkag
drug
cellular
intern
second
involv
format
stabl
noncoval
complex
drug
nowaday
cpp
constitut
promis
tool
noninvas
cellular
import
cargo
success
appli
vitro
vivo
deliveri
therapeut
molecul
vari
small
chemic
molecul
nucleic
acid
protein
peptid
liposom
particl
review
focu
structurefunct
cellular
uptak
mechan
cpp
gener
context
drug
deliveri
also
highlight
applic
peptid
carrier
deliveri
therapeut
molecul
provid
updat
clinic
evalu
peptidebas
drug
deliveri
technolog
f
heitz
et
al
british
journal
pharmacolog
peptidebas
drug
deliveri
technolog
f
heitz
et
al
british
journal
pharmacolog
peptidebas
drug
deliveri
technolog
f
heitz
et
al
british
journal
pharmacolog
peptidebas
drug
deliveri
technolog
f
heitz
et
al
british
journal
pharmacolog
past
year
order
circumv
limit
small
moleculeand
genebas
therapi
wit
dramat
acceler
product
new
larg
therapeut
molecul
follow
lipinski
rule
protein
peptid
nucleic
acid
therapeut
howev
develop
restrict
specif
issu
includ
poor
stabil
vivo
lack
cellular
uptak
insuffici
capabl
reach
target
associ
complet
loss
pharmaceut
potenc
least
requir
high
dose
risk
major
side
effect
therefor
deliveri
constitut
major
piec
therapeut
puzzl
real
demand
new
effici
drug
deliveri
system
major
rule
satisfi
particular
deliveri
effici
differ
challeng
cell
line
ii
rapid
endosom
releas
iii
abil
reach
target
iv
activ
low
dose
v
lack
toxic
vi
facil
therapeut
applic
substanti
progress
made
design
new
technolog
improv
cellular
uptak
therapeut
compound
opalinska
gewirtz
langel
glover
et
al
torchilin
de
fougerol
et
al
kong
mooney
number
nonvir
strategi
propos
includ
lipid
polycation
nanoparticl
peptidebas
formul
report
special
issu
morri
et
al
ogri
wagner
langel
torchilin
subset
technolog
effici
appli
vivo
either
preclin
clinic
level
protein
transduct
domain
ptd
cellpenetr
peptid
cpp
correspond
short
residu
synthet
peptid
part
promis
strategi
overcom
extracellular
intracellular
limit
variou
biomolecul
includ
plasmid
dna
oligonucleotid
sirna
peptidenucl
acid
pna
protein
peptid
well
liposom
cpp
trigger
movement
cargo
across
cell
membran
cytoplasm
cell
improv
intracellular
rout
therebi
facilit
interact
target
derossi
et
al
fawel
et
al
pooga
et
al
wender
et
al
deshay
et
al
mead
dowdi
morri
et
al
twenti
year
ago
notion
ptd
propos
base
observ
protein
mainli
transcript
factor
could
shuttl
within
cell
one
cell
anoth
histor
first
observ
made
frankel
pabo
show
transcriptiontransactiv
tat
protein
could
enter
cell
transloc
nucleu
frankel
pabo
group
prochiantz
demonstr
drosophila
antennapedia
homeodomain
could
intern
neuron
cell
joliot
et
al
work
origin
discoveri
first
ptd
cpp
deriv
form
third
helix
homeodomain
antennapedia
term
penetratin
rqikiyfqnrrmkwkk
derossi
et
al
group
lebleu
identifi
minim
peptid
sequenc
tat
requir
cellular
uptak
ygrkkrrqrrr
vive
et
al
first
noncoval
cpp
deliveri
nucleic
acid
mpg
design
group
heitz
divita
morri
et
al
close
follow
develop
noncoval
cellular
deliveri
protein
peptid
morri
et
al
group
wender
futaki
demonstr
polyarginin
sequenc
suffici
drive
molecul
cell
propos
uptak
mechan
involv
bident
hydrogenbond
interact
guanidinium
group
arginin
residu
phosphat
group
membran
wender
et
al
futaki
et
al
major
breakthrough
cpp
field
came
first
proofsofconcept
vivo
applic
group
dowdi
deliveri
small
peptid
larg
protein
schwarz
et
al
langel
deliveri
pna
use
chimer
peptid
transportan
deriv
form
ntermin
fragment
neuropeptid
galanin
link
mastoparan
wasp
venom
peptid
pooga
et
al
ever
sinc
mani
cpp
abl
trigger
movement
cargo
across
cell
membran
cytoplasm
design
langel
joliot
prochiantz
deshay
et
al
snyder
dowdi
cpp
gener
peptid
less
amino
acid
deriv
natur
unnatur
protein
chimer
sequenc
subdivid
two
main
class
first
requir
chemic
linkag
cargo
second
involv
format
stabl
noncoval
complex
cpp
also
distinguish
structur
point
view
either
polycation
essenti
contain
cluster
polyarginin
primari
sequenc
amphipath
repres
cpp
report
tabl
although
review
mainli
focus
cpp
base
natur
amino
acid
recent
new
concept
cpp
contain
unnatur
modifi
residu
propos
order
improv
either
stabil
effici
carrier
farrerasinfreu
et
al
cellpenetr
peptidebas
technolog
describ
far
mainli
involv
format
coval
conjug
cargo
carrier
peptid
achiev
chemic
crosslink
clone
follow
express
cpp
fusion
protein
nagahara
et
al
gait
moulton
moulton
zatsepin
et
al
work
report
peptid
deriv
tat
fawel
et
al
vive
et
al
frankel
pabo
penetratin
derossi
et
al
polyarginin
peptid
sequenc
wender
et
al
futaki
et
al
transportan
pooga
et
al
proteinderiv
peptid
protein
herp
simplex
viru
elliott
ohar
pvec
elmquist
et
al
calcitoninderiv
peptid
schmidt
et
al
krauss
et
al
antimicrobi
peptid
buforin
synb
park
et
al
park
et
al
well
polyprolin
sweet
arrow
peptid
pujal
et
al
also
success
use
improv
deliveri
coval
link
cargo
joliot
prochiantz
elandaloussi
et
al
murriel
dowdi
recent
new
gener
cpp
combin
differ
transduct
motif
abe
et
al
transduct
domain
tandem
protein
oligonucleotidebind
domain
mead
dowdi
propos
differ
chemistri
propos
stabl
cleavabl
conjug
involv
mainli
disulfid
thioester
linkag
accord
stabil
effici
cargo
sever
paramet
need
consid
includ
type
linkag
chemistri
natur
spacer
gait
zatsepin
et
al
coval
strategi
mainli
report
deliveri
dna
mimic
molecul
steric
block
oligonucleotid
includ
pna
koppelhu
et
al
fabani
et
al
phosphorodiamid
morpholinooligom
pmo
abe
et
al
lebleu
et
al
moulton
moulton
peptid
protein
snyder
dowdi
conjug
method
offer
sever
advantag
vivo
applic
includ
ration
reproduc
procedur
togeth
control
stoechiometri
cppcargo
howev
coval
cpp
technolog
limit
chemic
point
view
risk
alter
biolog
activ
cargo
particularli
true
case
charg
oligonucleotid
sirna
cpp
coupl
led
restrict
biolog
activ
juliano
et
al
noncoval
strategi
therebi
appear
appropri
strategi
mainli
base
short
amphipath
peptid
carrier
consist
two
domain
hydrophil
polar
domain
hydrophob
nonpolar
domain
tabl
amphipath
charact
may
aris
either
primari
structur
secondari
structur
primari
amphipath
peptid
defin
sequenti
assembl
domain
hydrophob
residu
domain
hydrophil
residu
secondari
amphipath
peptid
gener
conform
state
allow
posit
hydrophob
hydrophil
residu
opposit
side
molecul
deshay
et
al
sever
cpp
report
form
noncoval
complex
biomolecul
improv
deliveri
mammalian
cell
noncoval
approach
origin
develop
gene
deliveri
sever
peptid
abl
condens
dna
associ
peptid
favour
endosom
escap
includ
fusion
peptid
ha
subunit
influenza
hemaglutinin
describ
lear
degrado
parent
et
al
synthet
peptid
analog
gala
kala
gottschalk
et
al
wyman
et
al
rittner
et
al
mpg
morri
et
al
histidinerich
peptid
midoux
et
al
kichler
et
al
also
report
potent
gene
deliveri
system
demonstr
amphipath
peptid
could
success
appli
deliveri
small
peptid
protein
noncoval
approach
morri
et
al
noncoval
strategi
base
mpg
shown
effici
deliv
sirna
cultur
cell
line
simeoni
et
al
mpg
primari
amphipath
peptid
contain
hydrophil
lysinerich
domain
deriv
nuclear
local
sequenc
nl
larg
antigen
kkkrkv
variabl
ntermin
hydrophob
moieti
deriv
form
fusion
sequenc
hiv
protein
galflgflgaagstmga
mpg
tryptophanrich
cluster
ketwwetwwtew
separ
linker
domain
improv
flexibl
integr
hydrophob
hydrophil
domain
morri
et
al
morri
et
al
simeoni
et
al
mpg
form
stabl
complex
respect
cargo
oligonucleotid
proteinpeptid
noncoval
electrostat
hydrophob
interact
morri
et
al
simeoni
et
al
gro
et
al
munozmorri
et
al
noncoval
strategi
protein
oligonucleotid
deliveri
recent
extend
cpp
includ
tat
mead
dowdi
polyarginin
kim
et
al
kumar
et
al
transportanderiv
peptid
pooga
et
al
lundberg
et
al
cellular
uptak
mechan
cpp
essenti
piec
puzzl
develop
optim
appropri
strategi
vivo
therapeut
applic
although
cellular
intern
cpp
report
wide
varieti
cell
type
mechan
intern
remain
mysteri
long
time
independ
endocytosi
energi
specif
receptor
last
year
cpp
field
suffer
learnt
technic
artifact
lebleu
colleagu
propos
revis
cellular
uptak
mechan
cpp
essenti
associ
endosom
pathway
richard
et
al
ever
sinc
mechan
mani
cpp
reexamin
report
mediat
endocytosi
lundberg
johansson
nakas
et
al
wadia
et
al
fischer
et
al
richard
et
al
murriel
dowdi
howev
cpp
cellular
uptak
mechan
still
need
confirm
remain
controversi
partli
due
fact
differ
method
compar
one
lab
peptidebas
drug
deliveri
technolog
f
heitz
et
al
anoth
employ
aim
therefor
result
taken
care
case
visual
cpp
insid
cell
base
fluoresceinlabel
cpp
risk
fluoresc
dye
may
alter
uptak
mechan
trigger
unusu
cell
entri
pathway
reflect
biolog
activ
fraction
cpp
cargo
evid
sever
rout
entri
report
independ
endosom
pathway
involv
transmembran
potenti
terron
et
al
thoren
et
al
rothbard
et
al
deshay
et
al
therefor
therapeut
purpos
challeng
remain
identifi
rout
yield
biolog
respons
may
predomin
one
correl
uptak
pathway
biolog
respons
associ
specif
cargo
wadia
et
al
gro
et
al
purpos
sever
approach
describ
use
biolog
report
wadia
et
al
lebleu
et
al
phenotyp
morri
et
al
assay
enabl
follow
shuttl
releas
cargo
real
time
cultur
cell
lee
et
al
anim
model
wender
et
al
although
remain
difficult
establish
gener
scheme
cpp
uptak
mechan
consensu
first
contact
cpp
cell
surfac
take
place
electrostat
interact
proteoglycan
cellular
uptak
pathway
driven
sever
paramet
includ
natur
secondari
structur
cpp
ii
abil
interact
cell
surfac
membran
lipid
compon
iii
natur
type
activ
concentr
cargo
iv
cell
type
membran
composit
figur
proteoglycan
play
essenti
role
regul
cell
surfac
microdomain
evid
direct
relationship
cytoskelet
organ
activ
small
gtpase
clearli
establish
conner
schmid
eitzen
heparan
sulfat
proteoglycan
syndecan
major
compon
extracellular
matrix
cluster
trigger
cytoskelet
remodel
upon
activ
protein
kinas
c
rhorac
gtpase
control
dynam
cholesterolrich
raft
microdomain
therefor
ligand
bind
cellular
uptak
pathway
couchman
beauvai
rapraeg
first
contact
cpp
cell
surfac
take
place
electrostat
bind
cell
surfac
proteoglycan
glucosaminoglycan
gag
platform
follow
remodel
actin
network
select
activ
remain
earli
late
endosom
deliv
golgi
apparatu
endoplasm
reticulum
duchardt
et
al
ziegler
gtpase
activ
actin
remodel
constitut
onset
intern
mechan
major
impact
membran
fluiditi
therebi
promot
cell
entri
arg
penetratin
tat
via
macropinocytosi
nakas
et
al
clathrindepend
endocytosi
richard
et
al
mpg
particl
via
membran
perturb
mechan
gerbalchaloin
et
al
follow
bind
gag
platform
facilit
accumul
cpp
cppcargo
complex
cell
surfac
differ
cell
entri
gate
report
depend
cpp
correl
cellular
uptak
cargoassoci
biolog
respons
major
requir
valid
effici
cpp
origin
establish
tat
wadia
et
al
extend
seri
wellknown
cpp
nakas
et
al
padari
et
al
one
major
differ
cpp
resid
mode
interact
cellular
surfac
compon
interact
peptid
tat
consol
et
al
murriel
dowdi
polyarginin
penetratin
nakas
et
al
extracellular
matrix
report
primarili
electrostat
trigger
uptak
energydepend
endocytot
process
rusnati
et
al
murriel
dowdi
although
macropinocytosi
report
major
rout
intern
cation
cpp
wadia
et
al
kaplan
et
al
endocytot
pathway
includ
clathrinand
caveolindepend
endocytosi
richard
et
al
ziegler
et
al
transgolgi
networkmedi
intern
fischer
et
al
describ
cpp
moreov
differ
mechan
membran
transloc
endocytosi
may
concur
simultan
cpp
especi
true
amphipath
peptid
tend
interact
lipid
adopt
secondari
structur
within
membran
modifi
membran
integr
secondari
structur
cpp
dynam
constitut
major
factor
mechan
cellular
uptak
magzoub
deshay
et
al
esbjorn
et
al
increas
local
concentr
cpp
cell
surfac
favour
cellular
uptak
independ
endocytosi
lead
cytoplasm
distribut
cpp
inde
major
rout
cell
entri
cppbase
nanoparticl
mpg
shown
independ
endosom
pathway
cellular
uptak
associ
abil
mpg
interact
membran
lipid
mainli
hydrophob
domain
form
transient
transmembran
helic
beta
structur
temporarili
affect
membran
organ
therebi
facilit
insert
membran
initi
transloc
process
associ
membran
potenti
deshay
et
al
b
cellular
uptak
biolog
activ
mpgcargo
complex
directli
correl
structur
nanoparticl
creat
local
high
concentr
peptid
cell
surfac
gro
et
al
munozmorri
et
al
contrast
cellular
uptak
well
character
subset
cpp
littl
known
cellular
traffick
import
allow
cargo
reach
target
within
cell
clearli
endosom
escap
remain
major
limit
ratelimit
step
cppmediat
drug
deliveri
small
fraction
cpp
abl
escap
endosom
throughout
either
endosom
breaker
properti
fact
poor
integr
macropinocytosi
vesicl
sever
studi
report
cpp
traffic
endoplasm
reticulum
golgi
network
via
retrograd
pathway
involv
cytosol
releas
fischer
et
al
moreov
cpp
harbour
function
nl
motif
directli
local
trigger
cargo
nucleu
cartier
reszka
simeoni
et
al
number
applic
use
cpp
conscious
increas
far
studi
use
either
coval
noncoval
cppbase
strategi
vitro
vivo
report
dietz
gro
et
al
moscho
et
al
patel
et
al
foerg
merkl
interest
cpp
mainli
due
low
cytotox
fact
limit
type
cargo
although
cpp
use
improv
deliveri
cargo
vari
greatli
size
natur
small
molecul
oligonucleotid
plasmid
dna
peptid
protein
nanoparticl
lipidbas
formul
viru
quantum
dot
applic
describ
deliveri
oligopeptideprotein
dietz
gro
et
al
patel
et
al
nucleic
acid
analog
juliano
et
al
tabl
poor
permeabl
plasma
membran
eukaryot
cell
dna
togeth
low
effici
dna
oligonucleotid
reach
target
within
cell
constitut
two
major
barrier
develop
therapeut
molecul
last
decad
number
peptid
carrier
combin
dna
bind
mainli
electrostat
domain
polylysin
polyarginin
membranedestabil
properti
develop
facilit
gene
transfer
cultur
cell
live
anim
niidom
huang
glover
et
al
morri
et
al
amphipath
peptid
phdepend
fusogen
endosomolyt
activ
fusion
peptid
ha
subunit
influenza
hemaglutinin
synthet
analog
gala
kala
histidinerich
peptid
shown
increas
transfect
effici
associ
polyllysinedna
condens
peptidedna
cation
lipid
polyethyleneimin
polyamidoamin
cascad
polym
review
morri
et
al
singl
peptid
chain
abl
condens
dna
favour
endosom
escap
rittner
et
al
prevent
endosom
uptak
mpg
morri
et
al
also
use
gene
deliveri
cultur
cell
howev
cpp
valid
vivo
gene
deliveri
far
secondari
amphipath
peptid
constitut
one
exampl
report
signific
vivo
gene
express
respons
follow
intraven
inject
rittner
et
al
tat
transportan
polyarginin
cpp
peptidebas
drug
deliveri
technolog
f
heitz
et
al
associ
lipidbas
nonvir
gene
deliveri
method
includ
liposom
pei
nanostructur
branden
et
al
tung
et
al
ignatovich
et
al
rudolph
et
al
kilk
et
al
associ
tat
octaarginin
pharmaceut
nanocarri
describ
nonvir
deliveri
system
base
new
pack
concept
program
packag
multifunct
envelopetyp
nanodevic
mend
kogur
et
al
mackay
et
al
shown
improv
gene
deliveri
offer
advantag
combin
deliveri
packag
target
motif
within
particl
torchilin
et
al
second
major
barrier
nonvir
gene
deliveri
system
poor
nuclear
transloc
howev
essenti
transfect
nondivid
cell
gene
therapi
order
improv
nuclear
deliveri
dnaplasmid
synthet
peptid
contain
nl
extens
appli
cartier
reszka
escriou
et
al
studi
perform
sequenc
deriv
larg
antigen
nl
pkkkrkv
sequenc
associ
either
membranepenetr
cation
peptid
also
directli
link
cargo
combin
transfect
method
facilit
deliveri
nucleu
moreov
nl
sequenc
associ
differ
hydrophob
cpp
order
favour
nuclear
target
well
dna
bind
compact
nl
domain
mpg
shown
improv
nuclear
transloc
nucleic
acid
without
requir
nuclear
membran
breakdown
mitosi
mpg
technolog
appli
plasmid
dna
oligonucleotid
deliveri
high
effici
larg
number
adher
suspens
cell
line
simeoni
et
al
morri
et
al
steric
block
small
neutral
oligonucleotid
includ
pna
phosphorodiamid
morphorodiamid
morpholinooligom
pmo
constitut
potent
molecul
either
antisens
applic
mrna
splice
correct
strategi
sever
cpp
success
appli
deliveri
uncharg
pna
pmo
vitro
vivo
coval
coupl
gait
moulton
moulton
zatsepin
et
al
juliano
et
al
origin
report
transportan
vivo
deliveri
antisens
pna
target
galanin
receptor
modifi
pain
transmiss
pooga
et
al
use
cpp
steric
block
oligonucleotid
deliveri
extend
tat
penetratin
short
version
transportan
argininerich
peptid
sever
cppbase
coval
approach
report
deliveri
antisens
pna
koppelhu
nielsen
howev
use
vivo
recent
none
report
activ
submicromolar
concentr
gait
abe
et
al
detail
studi
cppmediat
pna
deliveri
report
major
limit
due
endosom
sequestr
koppelhu
nielsen
recent
new
cpp
describ
lebleu
gait
group
includ
acid
space
oligoarginin
rahxr
exhibit
limit
endosom
sequestr
lead
submicromolar
antisens
splice
correct
respons
abe
et
al
cpp
valid
vivo
splice
correct
two
therapeut
model
duchenn
muscular
dystrophi
fletcher
et
al
coronaviru
replic
mice
burrer
et
al
noncoval
strategi
also
appli
deliveri
pna
dna
mimic
molecul
nan
et
al
peptid
variant
success
appli
deliveri
pna
analog
target
cell
cycl
regulatori
protein
cyclin
vitro
vivo
interestingli
nanoparticl
organ
complex
allow
function
surfac
layer
particl
pegyl
carrier
significantli
improv
efficaci
respons
stabil
complex
studi
show
modif
improv
system
administr
mice
therebi
allow
signific
reduct
dose
requir
induc
specif
robust
biolog
respons
consequ
limit
nonspecif
cytotox
effect
describ
upon
treatment
high
concentr
cpppna
conjug
noncovalenti
complex
morri
et
al
decoy
oligonucleotid
short
interf
rna
sirna
constitut
power
biomed
tool
control
protein
activ
andor
gene
express
posttranscript
elbashir
et
al
hannon
howev
major
limit
sirna
applic
like
antisens
nucleic
acidbas
strategi
remain
poor
cellular
uptak
associ
poor
permeabl
cell
membran
nucleic
acid
sever
viral
nonvir
strategi
propos
improv
deliveri
either
sirnaexpress
vector
synthet
sirna
cultur
cell
vivo
de
fougerol
et
al
juliano
et
al
cppbase
strategi
develop
improv
deliveri
oligonucleotid
vitro
vivo
deliveri
charg
oligonucleotid
sirna
challeng
multipl
anion
charg
nucleic
acid
interact
cpp
moieti
inhibit
uptak
steric
hindranc
deliveri
charg
oligonucleotid
achiev
use
either
peptidebas
noncoval
pnahybrid
strategi
latter
cpp
coval
link
pna
abl
hybrid
doublestrand
decoy
oligonucleotid
contain
one
strand
flank
sequenc
complementari
pna
strategi
appli
transportan
cpp
deliveri
decoy
oligonucleotid
interact
nfkb
myc
fisher
et
al
elandaloussi
et
al
mpg
peptidebas
deliveri
system
success
appli
deliveri
variou
type
nucleic
acid
includ
phosphodiesteroligonucleotid
target
protein
phosphatas
morri
et
al
phosphorothioateoligonucleotid
target
promot
human
cem
leukaemia
cell
marthinet
et
al
thiophosphoramid
telomeras
templat
antagonist
cancer
cell
gryaznov
et
al
sever
cppbase
strategi
use
deliveri
sirna
cultur
cell
sirna
coval
link
transportan
muratovska
eccl
penetratin
davidson
et
al
associ
silenc
respons
nevertheless
noncoval
strategi
appear
appropri
sirna
deliveri
yield
signific
associ
peptidebas
drug
deliveri
technolog
f
heitz
et
al
biolog
respons
simeoni
et
al
kim
et
al
veldhoen
et
al
crombez
et
al
kumar
et
al
lundberg
et
al
mead
dowdi
mpg
peptid
report
improv
sirna
deliveri
larg
panel
cell
line
includ
adher
cell
line
cell
suspens
cancer
challeng
primari
cell
line
simeoni
et
al
morri
et
al
nguyen
et
al
mpg
appli
vivo
deliveri
sirna
target
mous
blastocyt
zeineddin
et
al
sirna
target
essenti
cell
cycl
protein
cyclin
intraven
inject
mpgcyclin
sirna
particl
shown
effici
block
tumour
growth
crombez
et
al
variant
mpg
mpgalpha
harbour
five
mutat
hydrophob
domain
order
favour
helic
conform
peptid
also
shown
improv
sirna
deliveri
veldhoen
et
al
howev
modif
mpg
increas
toxic
favour
endosom
cellular
uptak
deshay
et
al
veldhoen
et
al
noncoval
approach
extend
cpp
includ
polyarginin
kim
et
al
kumar
et
al
penetratin
lundberg
et
al
tat
mead
dowdi
deriv
peptid
tat
peptid
associ
rnabind
motif
report
block
vivo
epiderm
growth
factor
egf
factor
shown
enhanc
sirna
deliveri
vivo
vascular
endotheli
growth
factor
kim
et
al
recent
small
peptid
deriv
rabi
viru
glycoprotein
associ
polyarginin
shown
deliv
sirna
cn
kumar
et
al
order
circumv
technolog
problem
gene
deliveri
increas
interest
taken
design
novel
strategi
enabl
deliveri
peptid
fulllength
protein
larg
number
cell
first
proof
concept
vivo
potenc
cpp
provid
dowdi
colleagu
show
tatbgalactosidas
fusion
protein
deliv
almost
tissu
includ
brain
follow
intraperiton
inject
mice
schwarz
et
al
last
decad
cppbase
deliveri
success
use
deliv
peptid
protein
target
differ
diseas
includ
cell
proliferationcanc
asthma
apoptosi
ischaemia
stimul
cytotox
immun
diabet
dietz
snyder
dowdi
gro
et
al
applic
use
cpp
tat
penetratin
polyarginin
coval
link
peptid
fusion
protein
recent
vivo
applic
technolog
describ
includ
intraven
intratumour
intratrach
inject
well
transduct
oocyt
spray
nasal
deliveri
direct
penetr
skin
gro
et
al
morri
et
al
one
princip
applic
cpp
involv
deliveri
peptid
protein
cancer
antiprolifer
treatment
tumour
suppressor
constitut
choic
target
differ
peptid
coval
link
cpp
demonstr
restor
function
cancer
cell
tatmedi
deliveri
peptid
deriv
form
cterminu
reduc
tumour
growth
upon
intraperiton
inject
mice
bcell
lymphoma
snyder
et
al
tang
et
al
similarli
peptid
deriv
domain
link
penetratin
describ
block
tumour
growth
michl
et
al
bown
et
al
anoth
success
antiprolifer
applic
report
use
peptid
deriv
nterminu
smac
protein
inactiv
inhibitor
apoptosi
protein
kim
et
al
smac
peptid
associ
cpp
sensit
cell
proapoptot
stimulu
synerget
effect
smac
peptid
tnfrelat
apoptosi
induc
ligand
shown
intracrani
glioblastoma
xenograft
mice
fulda
et
al
peptid
protein
domain
deriv
natur
protein
inhibitor
ink
kip
cyclindepend
kinas
involv
cell
cycl
progress
use
block
cancer
cell
prolifer
tumour
suppressor
function
vivo
report
use
kip
tumour
suppressor
protein
genet
coupl
tat
nagahara
et
al
snyder
et
al
well
ink
deriv
peptid
associ
penetratin
hosotani
et
al
small
peptid
inhibitor
cyclindepend
kinas
activ
deliv
use
noncoval
approach
shown
block
cancer
cell
prolifer
gondeau
et
al
cpp
also
use
target
bcell
lymphoma
oncogen
peptid
ebv
epstein
barr
viru
associ
tat
block
prolifer
knight
et
al
tatmedi
peptid
inhibitor
deliveri
report
modul
bcell
phenotyp
polo
et
al
melnick
strategi
also
appli
evalu
antitumour
activ
peptid
inhibitor
protein
kinas
repair
defect
step
cellular
signal
pathway
vivo
gro
et
al
morri
et
al
deregul
apoptosi
directli
indirectli
associ
mani
patholog
sever
success
applic
cppassist
deliveri
protein
peptid
regul
apoptosi
report
tatflip
caspas
inhibitor
fusion
peptid
interfer
activ
fa
induc
signal
complex
therebi
prevent
apoptosi
vivo
krautwald
et
al
peptid
issu
homolog
domain
protein
associ
tat
regul
apoptosi
induc
cytoprotect
vivo
sugioka
et
al
survivin
mutant
associ
tat
facilit
apoptosi
cancer
cell
wadia
et
al
strategi
appli
vivo
deliveri
protein
lung
mice
produc
alveolar
wall
apoptosi
correct
defect
protein
kinas
function
aoshiba
et
al
maron
et
al
abil
cpp
cross
blood
brain
barrier
favour
deliveri
protein
brain
use
improv
outcom
ischaem
event
death
neuron
cell
follow
cerebr
ischaemia
associ
apoptosi
tatbclxl
protein
deliv
mous
brain
decreas
neuron
cell
death
area
ischaem
damag
cao
et
al
reduct
cerebr
ischaemia
protect
ischaemia
brain
injuri
report
tatcjnk
peptid
tatbclx
protein
cao
et
al
peptid
select
inhibitor
pkcg
report
attenu
heart
ischaemia
bright
et
al
cpp
also
use
deliveri
small
molecul
blood
brain
barrier
dpenetratin
report
significantli
increas
uptak
doxorubicin
brain
roussel
et
al
technolog
also
demonstr
potent
strategi
deliv
therapeut
protein
vivo
across
blood
brain
barrier
gallo
et
al
aoshiba
et
al
gallo
maron
et
al
gro
et
al
cellpenetr
peptid
also
use
treatment
asthma
use
domin
neg
form
ra
phopshoinositol
kinas
fuse
tat
inhibit
airway
inflammatori
respons
cytokin
blockag
mous
myou
et
al
differ
protein
peptid
coupl
tat
penetratin
use
immun
specif
infecti
diseas
tat
peptid
also
use
deliveri
modular
antigen
molecul
use
treatment
allergi
vaccin
product
rhyner
et
al
superoxid
dismutas
sod
fuse
tat
shown
protect
pancreat
beta
cell
oxid
stress
eum
et
al
numer
preclin
clinic
evalu
cppbase
deliveri
approach
current
evalu
first
cpp
clinic
trial
initi
year
ago
cell
gate
inc
topic
deliveri
cyclosporin
link
polyarginin
enter
phase
ii
trial
rothbard
et
al
ever
sinc
sever
compani
work
clinic
develop
cpp
topic
system
administr
differ
therapeut
molecul
avi
biopharma
vivo
steric
block
splice
correct
use
acid
space
oligoarginin
rahxr
lebleu
et
al
moulton
moulton
kai
pharmaceut
chen
harrison
current
evalu
tat
protein
kinas
c
inhibitor
peptid
modul
protein
kinas
c
acut
myocardi
infract
cerebr
ischaemia
enter
phase
ii
compani
includ
traversa
inc
tatbas
noncoval
sirna
deliveri
panom
inc
secondari
amphipath
peptidebas
noncoval
deliveri
sirna
current
evalu
cpp
preclin
clinic
trial
dramat
acceler
discoveri
new
highli
potent
therapeut
molecul
howev
make
clinic
due
poor
deliveri
low
bioavail
lack
ration
target
made
clear
deliveri
key
stone
therapeut
develop
kong
mooney
accordingli
carrier
peptid
repres
new
innov
concept
bypass
problem
bioavail
associ
certain
drug
peptid
protein
nucleic
acid
current
rare
consid
therapeut
due
abovement
limit
peptidebas
strategi
present
sever
advantag
includ
rapid
deliveri
cargo
cell
high
effici
stabil
physiolog
buffer
lack
toxic
sensit
serum
twenti
year
discoveri
cpp
door
clinic
success
report
preclin
evalu
cpp
last
decad
reveal
tremend
potenti
clinic
treatment
coval
strategi
valid
protein
peptid
deliveri
recent
success
phase
ii
clinic
trial
open
great
hope
use
cpp
therapi
moreov
introduct
cppbase
noncoval
strategi
allow
introduct
oligonucleotid
sirna
preclin
state
lack
prerequisit
coval
coupl
upon
format
carrier
macromolecul
particl
favour
intracellular
rout
cargo
enabl
control
releas
target
cellular
compart
whatev
natur
deliveri
system
major
attent
paid
target
carrierdrug
order
mediat
drug
deliveri
specif
cell
type
limit
dispers
whole
bodi
